BIOCRYST PHARMACEUTICALS INC financial data

Symbol
BCRX on Nasdaq
Location
Durham, NC
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 223% % -24%
Quick Ratio 3.2% % -64%
Debt-to-equity -237% %
Return On Equity -76% % -508%
Return On Assets 56% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 250,800,620 shares 20%
Common Stock, Shares, Outstanding 213,060,000 shares 2.2%
Entity Public Float $1,863,392,680 USD 47%
Common Stock, Value, Issued $2,131,000 USD 2.2%
Weighted Average Number of Shares Outstanding, Basic 209,893,000 shares 1.5%
Weighted Average Number of Shares Outstanding, Diluted 218,581,000 shares 5.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $166,126,000 USD -4.9%
Costs and Expenses $533,848,000 USD 18%
Operating Income (Loss) $340,989,000 USD
Nonoperating Income (Expense) $73,598,000 USD 13%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $267,391,000 USD
Income Tax Expense (Benefit) $3,530,000 USD 83%
Net Income (Loss) Attributable to Parent $263,861,000 USD
Earnings Per Share, Basic 1.26 USD/shares
Earnings Per Share, Diluted 1.21 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $89,736,000 USD -14%
Accounts Receivable, after Allowance for Credit Loss, Current $106,818,000 USD 35%
Inventory, Net $5,398,000 USD -33%
Assets, Current $404,346,000 USD -4.2%
Property, Plant and Equipment, Net $8,783,000 USD 13%
Operating Lease, Right-of-Use Asset $7,548,000 USD -6.4%
Other Assets, Noncurrent $5,672,000 USD 10%
Assets $514,158,000 USD 4.8%
Accounts Payable, Current $15,826,000 USD 36%
Employee-related Liabilities, Current $50,857,000 USD 4.6%
Accrued Liabilities, Current $126,413,000 USD 12%
Liabilities, Current $196,066,000 USD 22%
Operating Lease, Liability, Noncurrent $8,571,000 USD 8.2%
Liabilities $633,311,000 USD -34%
Accumulated Other Comprehensive Income (Loss), Net of Tax $38,000 USD -96%
Retained Earnings (Accumulated Deficit) $1,506,179,000 USD 15%
Stockholders' Equity Attributable to Parent $119,153,000 USD 75%
Liabilities and Equity $514,158,000 USD 4.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $27,517,000 USD 49%
Net Cash Provided by (Used in) Financing Activities $529,000 USD
Net Cash Provided by (Used in) Investing Activities $27,095,000 USD -5.8%
Common Stock, Shares Authorized 450,000,000 shares 0%
Common Stock, Shares, Issued 213,060,000 shares 2.2%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $558,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $91,337,000 USD -14%
Interest Paid, Excluding Capitalized Interest, Operating Activities $9,153,000 USD 84%
Deferred Tax Assets, Valuation Allowance $380,519,000 USD -15%
Deferred Tax Assets, Gross $384,353,000 USD -15%
Operating Lease, Liability $8,888,000 USD 0.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $262,978,000 USD
Lessee, Operating Lease, Liability, to be Paid $14,682,000 USD 0.91%
Property, Plant and Equipment, Gross $18,177,000 USD -9.7%
Operating Lease, Liability, Current $317,000 USD -66%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,462,000 USD -16%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,153,000 USD -38%
Operating Lease, Weighted Average Discount Rate, Percent 0.107 pure -1.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $5,794,000 USD 1.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,506,000 USD -8.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $14,498,000 USD -1.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,538,000 USD 11%
Operating Lease, Payments $385,000 USD -27%
Additional Paid in Capital $1,384,857,000 USD 7.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $331,000 USD 8.2%
Share-based Payment Arrangement, Expense $85,066,000 USD 30%
Interest Expense $101,167,000 USD -5.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%